vrtx news - Search News

MarketWatch · 1h

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Hosted on MSN · 1d

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Business Insider · 2d

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price

MarketWatch · 1d

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

The Motley Fool · 12h

Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?

The FDA is scheduled to make an approval decision for suzetrigine in treating acute pain by Jan. 30, 2025. This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years.

5h

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

10h

Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

2d

Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

2d

Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

1d

Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Hosted on MSN22d

Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...

1don MSN

McKesson, Vertex Pharmaceuticals among top healthcare Quant picks before Q4 earnings

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

3d

International Assets Investment Management LLC Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...

2d

Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results